Common Blood Protein Unmasked as Key Defense Against Deadly Black Fungus

LOS ANGELES, CA – January 26, 2026 – In a landmark discovery that could reshape the fight against a notoriously lethal fungal infection, an international team of scientists has identified albumin, the most abundant protein in human blood, as a powerful, previously unknown defender against mucormycosis.

The study, published in the prestigious journal Nature, reveals that this common protein plays a critical role in neutralizing the aggressive molds that cause the disease, often called “black fungus.” The research, led by the University of Crete and featuring crucial contributions from a team at The Lundquist Institute for Biomedical Innovation, pinpoints low albumin levels as a key vulnerability and opens a promising new avenue for prevention and treatment.

The Scourge of Mucormycosis

Mucormycosis is a rare but devastating infection caused by Mucorales fungi, which are commonly found in soil and decaying organic matter. While harmless to most healthy individuals, the fungus can launch a swift, brutal assault on those with weakened immune systems, leading to a grim prognosis. The infection spreads rapidly through blood vessels, destroying tissue and causing black lesions, which give the disease its ominous nickname. Mortality rates are alarmingly high, exceeding 50% and approaching 100% in cases where the infection disseminates throughout the body.

High-risk groups include individuals with uncontrolled diabetes, cancer patients, organ transplant recipients, and those on long-term corticosteroid therapy. The global burden of the disease was cast into the spotlight during the COVID-19 pandemic, particularly in India, which experienced an unprecedented surge of cases. The confluence of COVID-19, widespread diabetes, and the use of steroids to treat the viral infection created a perfect storm for the fungus to thrive, overwhelming healthcare systems and leading to thousands of deaths. India is estimated to have a mucormycosis prevalence 80 times higher than that of developed nations.

Current treatment protocols are aggressive and often disfiguring. They typically involve a combination of high-dose intravenous antifungal drugs, such as amphotericin B, and radical surgical debridement to remove all infected and dead tissue. This can mean the removal of an eye, parts of the jaw, or sinus tissue. Despite these drastic measures, success is far from guaranteed, highlighting a desperate need for more effective and less invasive therapeutic options.

An Unexpected Defender in Our Blood

The new study offers a beacon of hope by identifying a defender that has been hiding in plain sight. Researchers discovered that patients suffering from mucormycosis consistently had significantly lower levels of serum albumin compared to patients with other fungal infections. This condition, known as hypoalbuminemia, emerged as the single strongest predictor of poor outcomes, including death, across diverse patient groups from multiple continents.

“This is a remarkable finding and has the potential to change the way clinicians care for mucormycosis,” said Dr. Ashraf Ibrahim, a professor at The Lundquist Institute and a senior author on the study. The research effectively establishes hypoalbuminemia as a critical biomarker for identifying patients at high risk of developing the deadly disease.

This insight suggests a paradigm shift in patient management. According to Dr. Ibrahim, this could lead to preventative strategies where at-risk patients “receive albumin loaded with free fatty acids to prevent the infection from taking place, which is the best way of dealing with mucormycosis given its aggressive nature.”

The protective power of albumin was confirmed through a series of decisive experiments. When scientists removed albumin from healthy human blood samples, the Mucorales fungi grew without restriction. In animal models, mice genetically engineered to lack albumin were highly susceptible to the infection. Conversely, restoring albumin levels in these mice conferred powerful protection against the disease, directly linking the protein to host defense.

Decoding the Mechanism of Attack

Beyond simply identifying albumin's protective role, the study delved into the specific biochemical mechanism behind its antifungal power. The researchers demonstrated that albumin’s potency is not derived from the protein itself, but from the fatty acids that it naturally binds to and transports throughout the bloodstream.

These albumin-bound fatty acids selectively disrupt the metabolism of Mucorales fungi. They effectively sabotage the production of key proteins and toxins that the fungus needs to cause tissue damage, invade human organs, and evade the immune system. This action is highly specific, inhibiting the growth of Mucorales while leaving other microbes unaffected, suggesting a finely tuned natural defense mechanism.

“The study also tells us how albumin works on nullifying critical virulence factors including toxins and other fungal proteins involved in causing tissue damage and in aggressively invading human organs,” Dr. Ibrahim explained. Blood analysis from mucormycosis patients revealed that the fatty acids in their systems showed increased oxidation, rendering them less effective at fighting the fungus and helping to explain why these individuals were so vulnerable.

This detailed understanding of the molecular battle between host and pathogen is crucial. It not only validates the potential of albumin therapy but also paves the way for more sophisticated treatments. The Lundquist Institute team is already exploring how albumin therapy could be paired with novel immunotherapies that target the specific virulence factors of Mucorales, potentially creating a powerful synergistic treatment regimen.

From Discovery to a Potential Lifeline

The identification of albumin as a key antifungal agent is more than just a scientific curiosity; it represents a tangible path toward a new clinical strategy. Human serum albumin is not a new or experimental compound. It is a well-understood biological product, approved by regulatory bodies like the FDA, and widely used in hospitals worldwide for conditions such as severe burns, shock, and liver disease. Its established safety profile and existing manufacturing infrastructure could significantly shorten the timeline for its development as a mucormycosis treatment.

This discovery opens the door to both preventative and therapeutic applications. High-risk patients, such as those with diabetic ketoacidosis or undergoing intensive chemotherapy, could potentially receive albumin infusions to bolster their defenses before an infection can take hold. For patients with an active infection, albumin therapy could be used alongside existing antifungals to weaken the fungus and improve treatment outcomes.

While the journey from laboratory discovery to a standard clinical protocol involves rigorous clinical trials to determine optimal dosing and efficacy, this breakthrough provides a clear and promising direction. By uncovering a fundamental component of the body’s own defense system, this research offers a new weapon against a terrifying disease. This newfound understanding of the body's innate defenses opens a critical new front in the battle against one of medicine's most formidable fungal foes.